Overview
Therapeutic Targeting of Oncogenic Transcription Factors
Transcription factors can induce profound and sustained phenotypic effects in cells by binding and altering the expression of thousands of genes. It is therefore not surprising that many of these factors have been shown to play critical roles in tumorigenesis, especially in the hematological malignancies. From the mechanistic standpoint transcription factors function by binding to a specific DNA consensus sequence, or by forming a complex with other transcription factors, and recruiting chromatin modifying complexes to their various genetic target loci. Because transcription factors mediate their action largely through protein-protein interactions rather than enzymatic activities they have been traditionally been regarded as "undruggable targets". However, we propose that this concept is outdated and that a rigorous study of the biochemical mechanism of action of these proteins can provide sufficient information for the rational design of therapeutic inhibitors. We hypothesize that it is possible to design potent, specific and clinically viable transcription factor inhibitors. Such transcription therapy drugs would be predicted to therapeutically reprogram tumor cells so that they would either die or cease to display the malignant phenotype. We further hypothesize that the downstream pathways of these transcription factors can be harnessed for the development of more potent combinatorial treatments that by offering powerful anti-tumor efficacy could reduce the need for cytotoxic drugs in the clinical setting. Finally, we predict that transcription therapy drugs could offer superior activity against chemo-resistant and semi-quiescent tumor repopulating cells, allowing for complete eradication of disease.
Transcriptional Programming in Normal and Malignant B-cells
Highlights
- 1
- 2Science (New York, N.Y.) · 2023
- 3Cancer discovery · 2021
Publications
Funding
Active
29 grants- MPISPORE: Adressing Health Disparities in LymphomaNational Cancer Institute · 2025–2030 · via MD Anderson Cancer Center· 3 renewalsU54CA302435-01
- MPICollaborative Subcontract with University of Texas M.D. Anderson Cancer Center and Dr. MelnickMD Anderson Cancer Center · 2024–2029No publications yetMDACC 253204-02
- Co-ITargeting MALT1 to Enhance Anti-Lymphoma Immunity and Response to ImmunotherapyNational Cancer Institute · 2023–2028R01CA282889-04
- Co-ICharacterizing stem cell-like B cell subpopulations and dissecting their role in tumorigenesisNational Cancer Institute · 2023–2028R01CA283327-01
- MPIDysregulated mechanoimmunology of epigenetics-driven lymphomasNational Cancer Institute · 2023–2028 · via Georgia Institute of TechnologyU01CA280984-01
- KPTranslating molecular profiles into treatment approaches to target disparities in lymphomaLeukemia & Lymphoma Society · 2024–2027 · via Emory UniversityLLS 7038-25
- MPITargeting Unmet Needs For B-cell LymphomasLeukemia & Lymphoma Society · 2022–2027LLS 7027-23 Project 1
- MPIDefine genetically/epigenetically modified targets in the immune niche of DLBCLs- Project 2Leukemia & Lymphoma Society · 2022–2027 · via University Health NetworkUHN 224060-04
- KPRole of chromatin remodeling complex BAF in immunity and lymphomaNational Cancer Institute · 2024–2027R00CA246080-03
- KPMechanisms of CTL Resistance in HIV ReservoirsNational Institute of Allergy and Infectious Diseases · 2022–2027
- Co-IBAF complex deregulation in lymphomaNational Cancer Institute · 2022–2027 · via MD Anderson Cancer Center
- MPIResearch Collaboration Agreement- Treeline Biosciences, Inc.Treeline Biosciences INC · 2024–2027BioPharma AllianceBP 240939-01
- KPPreventing follicular lymphoma progression and transformation through precision therapyNational Cancer Institute · 2022–2027R01CA270245-01
- KPThe Impact of Spaceflight and Radiation on Clonal HematopoiesisNational Aeronautics and Space Administration · 2023–202780NSSC23K0832
- Co-IThe impact of changes in chromatin architecture on cancer phenotypes and tumor progressionNational Cancer Institute · 2025–2027 · via New York University School of Medicine (Grossman)No publications yetP01CA229068-06A1
- MPITherapeutic Targeting of SIRT3 for Aggressive and Refractory LymphomasNational Cancer Institute · 2023–2027R01CA270243-03
- MPIEpigenetic basis and therapeutic interdiction of FL progressionLymphoma Research Foundation · 2023–2027LRF 226504-01
- KPElucidating the role of follicular dendritic cells in EZH2-mutated follicular lymphomaLymphoma Research Foundation · 2024–2026LRF 234088-01
- Co-IHow the immune system becomes malignantStarr Cancer Consortium · 2024–2026 · via Broad Institute IncI17-0131
- KPCharacterizing the role of BCL10 somatic mutations in B cell lymphomasLymphoma Research Foundation · 2024–2026LRF 234006-01
- KPUncovering immune evasion mechanisms and therapeutic targets in B-cell lymphomas via macrophage reprogrammingLeukemia & Lymphoma Society · 2025–2026LLS 3444-26
- Co-IRole of BCL10 somatic mutations in lymphomagenesis and response to BCR-targeted therapiesNational Cancer Institute · 2020–2026R01CA249843-01
- MPIEpigenetic basis and therapeutic targeting of the unique lymphoma immunological nicheNational Cancer Institute · 2024–2026P01CA272295-02
- KPThe role of SPEN and NOTCH2 mutations in pathogenesis of DLBCL.Lymphoma Research Foundation · 2024–2026LRF 234091-01
- Sub-PIUnderstanding resistance mechanisms to protein arginine methyltransransferase Inhibitors in LymphomaNational Cancer Institute · 2023–2026 · via Memorial Sloan Kettering Cancer CenterR01CA274249-03
- MPIPrecision epigenetic therapy for SETD2+/- B cell lymphomasLymphoma Research Foundation · 2023–2026LRF 226510-01
- Co-IThe role of chromatin loop extrusion in lymphomagenesis and therapeutic targeting - Project 1Leukemia & Lymphoma Society · 2024–2026 · via University of FloridaUSF 240838-01
- MPIDiscovery and therapeutic targeting of novel mechanisms driving Double Hit LymphomasLeukemia & Lymphoma Society · 2023–2025LLS 6679-24
- Co-IRole of the stromal microenvironment in B-cell lymphoma progression and immune escapeNational Cancer Institute · 2019–2025
Completed grants (98)
- Co-IInhibiting EZH2 to improve CAR T immunotherapy in B-cell lymphomasGilead Sciences, Inc. · 2023–2025GSI 231647-01
- PIThe Role of SPEN as Tumor Suppressor in BN2 DLBCLLeukemia & Lymphoma Society · 2022–2025LLS 8031-23
- PISETD2 and H1 ProjectEpizyme · 2021–2025BioPharma AllianceEI 214942-01
- MPITargeting immune escape in Cluster 5 DLBCLAstraZeneca Pharmaceuticals LP · 2021–2025ContractSRA 215352-01
- PITargeting Epigenetic Circuits in B-Cell LymphomasNational Cancer Institute · 2018–2025· 4 renewalsR35CA220499-07
- PIPrecision translation of therapeutic regimens for follicular lymphomaInstitute for Follicular Lymphoma Innovation, Inc. · 2022–2025IFLI 227301-02
- Co-IRole of novel onco-histone mutations in B-cell malignanciesNational Cancer Institute · 2019–2025
- PIBioPharma Alliance Agreement- Janssen Research & DevelopmentJanssen Research & Development, LLC · 2021–2025BioPharma AllianceBP 220122-03
- Sub-PILymphoid Experimental Therapeutics Platform to Study Cooperative Signaling in Human LymphomasNational Cancer Institute · 2020–2025 · via Cornell University - IthacaR01CA238745-04
- MPIThe impact of changes in chromatin architecture on cancer phenotypes and tumor progressionNational Cancer Institute · 2019–2025 · via New York University Medical Center· 2 renewalsP01CA229086-05
- KPLymph node-targeted multistage chemoimmunotherapy for lymphomaNational Cancer Institute · 2020–2025 · via Georgia Tech Research CorporationR01CA247484-03
- Sub-PIUnderstanding the in vivo impact of immunotherapies in splenic lymphoma by intravital three-photon microscopyNational Cancer Institute · 2023–2025 · via Cornell University - IthacaR21CA277513-02
- PIElucidating the role of follicular dendritic cells in EZH2-mutated follicular lymphoma progression and transformationThe Asco Cancer Foundation · 2023–2024ASCO 226835-01
- Co-IMechanisms of dynamic chromatin reorganization regulating B-cell differentiation and LymphomagenesisStarr Cancer Consortium · 2023–2024I16-068
- KPUtilizing EZH2 Inhibition to Improve Immune Therapies in Follicular LymphomaFollicular Lymphoma Foundation · 2022–2024FLF 224362-02
- MPIExploring the roles of EZH2 mutation for the development of double hit lymphoma and acquisition of chemotherapy resistanceLeukemia & Lymphoma Society · 2023–2024LLS 3426-24
- KPPreventing follicular lymphoma progression and transformation through precision therapyLeukemia & Lymphoma Society · 2021–2024LLS 6641-22
- Sub-PICore: Targeting Enhancer Dysfunction in Hematological Malignancy- Core BLeukemia & Lymphoma Society · 2019–2024 · via University of FloridaLLS SCOR 7021-20 CORE B
- Sub-PITargeting Enhancer Dysfunction in Hematological Malignancy- Project 5Leukemia & Lymphoma Society · 2019–2024 · via University of FloridaLLS SCOR 7021-20
- Co-IElucidating Metabolic Pathways Regulating Germinal Center B Cells And Derived LymphomasAmerican Society of Hematology Inc · 2021–2024ASH 210204-03
- KPRole of Chromatin Remodeling Complex BAF in Immunity and LymphomaNational Cancer Institute · 2020–2024· 2 renewals
- KPWeill Cornell Medicine (WCM) SPORE in Prostate CancerNational Cancer Institute · 2017–2023P50CA211024-05
- KPDisruption of epigenetic regulation of enhancers in the germinal center reaction drives clonal evolution in Follicular LymphomaNational Cancer Institute · 2020–2023FellowshipF31CA254302-01
- KPCohesin complex regulatory proteins and chromosomal architecture in normal and malignant B-cellsAmerican Society of Hematology Inc · 2022–2023ASH 220412-01
- PICharacterizing The Biological And Mechanistic Nature Of The Elusive Lymphoma Stem CellTri-Institutional Stem Cell Initiative (Weill Cornell) · 2021–2023Tri-Sci #2021-033
- KPMolecular and Translational Oncology ResearchNational Cancer Institute · 2017–2023Training
- KPUnderstanding the role of SPEN in DLBCLLymphoma Research Foundation · 2021–2023LRF 210839-01
- Sub-PIBiomaterials-based Germinal Center Niches for Understanding the B Cell Maturation and B cell receptor signalingNational Institute of Allergy and Infectious Diseases · 2018–2023 · via Cornell University - IthacaR01AI132738-02
- PIEpizyme BPA Pre-Clinical Studies of EZH2 Inhibitor initiating Immunotherapy against B-Cell LymphomaEpizyme · 2021–2022BioPharma AllianceBP 220027-01
- Co-IMechanisms of dynamic chromatin reorganization regulating B-cell maturation and lymphomagenesisStarr Cancer Consortium · 2021–2022I14-0020
- PISIRT3 TARGETED THERAPY FOR B-CELL LYMPHOMASDr. Ralph and Marian Falk Medical Research Trust · 2019–2022FALK 18448-20
- Co-IStandard Omics Measures for Astronauts (SOMA): Comprehensive Biomedical and Multiomic Profiling and the Aerospace Medicine BiobankNational Aeronautics and Space Administration · 2021–2022 · via Baylor College of MedicineNNX16AO69A
- Sub-PITherapeutic Implications of Altered Epigenetics and DNA Damage Responses in Hematologic DisordersLeukemia & Lymphoma Society · 2016–2022 · via University Health NetworkUHN LLS 9238-16
- MPIMSK SPORE in LymphomaNational Cancer Institute · 2016–2022 · via Sloan-Kettering Institute for Cancer Research· 2 renewalsP50CA192937-05
- PIMALT1 Degradation for the Treatment of Activated B-Cell Type Diffuse Large B-cell LymphomaDaedalus Fund for Innovation (Weill Cornell) · 2021–2022BioPharma AllianceBP 220266-01
- MPITargeting MALT1 to overcome resistance to immune checkpoint blockade in MCD-DLBCLAmerican Society of Hematology Inc · 2021–2022ASH 212696-01
- KPBasic Junior Faculty ASH Scholar AwardAmerican Society of Hematology Inc · 2020–2022ASH 202414-01
- KPSignaling to Chromatin Pathways in Regulation of Germinal Center B Cell Differentiation and LymphomaLymphoma Research Foundation · 2020–2022LRF 200713-01
- KPTOX as a putative oncosuppressor in DLBCLAmerican Society of Hematology Inc · 2020–2022ASH 202403-01
- KPThe role of EZH2 in lymphomagenesisU.S. Department of Defense · 2020–2022No publications yetW81XWH2010478
- Sub-PICharacterizing and Targeting the Follicular Lymphoma MicroenvironmentLeukemia & Lymphoma Society · 2019–2022 · via INSERM Delegue RegionalLLS TRP6593-20
- Sub-PITargeting deregulated epigenetic mechanisms in B-cell lymphomas.Leukemia & Lymphoma Society · 2019–2022 · via University of MelbourneUM 191547-03
- MPIClonal co-evolution of cancer and immune cells - tumor genomics meets immunologyGerman Cancer Aid - Deutsche Krebshilfe · 2021–2022 · via University of CologneUC 70113307
- MPIECOG-ACRIN Integrated Leukemia Translational Science Center (LTSC)National Cancer Institute · 2019–2022 · via Sloan-Kettering Institute for Cancer ResearchUG1CA233332-03
- Co-IBiomaterials-based Germinal Center Niches for Understanding the B Cell Maturation and B cell receptor signalingNational Institute of Allergy and Infectious Diseases · 2020–2022 · via Georgia Institute of TechnologyNo publications yetR01AI132728-04
- PIUnderstanding the role of SPEN in marginal zone B cell transformation using three-photon microscopyCornell University - Ithaca · 2021–2021CUI 211701-01
- PIBPARC Agreement- Dr. Ari MelnickJanssen Biotech Inc. · 2019–2021BioPharma AllianceBP 200517-01
- KPIdentifying therapeutic vulnerabilities of aggressive and therapy-resistant MCD/C5-DLBCLs.American Society of Hematology Inc · 2020–2021ASH 211129-01
- PITargeting Unmet Clinical Needs for B-Cell LymphomaLeukemia & Lymphoma Society · 2016–2021LLS 7012-16
- PI"Transcriptional regulation by hematopoietic BTB transcription factor"Chemotherapy Foundation, Inc. · 2021–2021CFI 212865-01
- PITranscriptional Targeting in Cancer TherapySamuel Waxman Cancer Research Foundation · 2019–2021No publications yetSWCRF 200299-02
- KPLinker Histone Mutations Mediate Lymphomagenesis Through a Novel Chromatin MechanismU.S. Department of Defense · 2019–2021W81XWH-19-1-0216
- PIPrecision medicine deployment of mechanism based Epigenetic – Immune therapy for B-cell lymphomaLeukemia & Lymphoma Society · 2018–2021LLS-TRP-6572-19
- KPThe role of BCL10 mutations in lymphomagenesisLeukemia & Lymphoma Society · 2018–20215483-19
- Sub-PIUnderstanding and Targeting Chemotherapy Resistance in Acute Myeloid LeukemiaNational Cancer Institute · 2015–2021 · via University of PennsylvaniaR01CA198089-05
- PIDesign and testing of small molecule compound inhibitors of MALT1.Janssen Biotech Inc. · 2018–2021ContractBP 190099-02
- PIDefining the cellular origin and mechanistic basis for therapy resistant B-cell lymphomasStarr Cancer Consortium · 2018–2020I11-0027
- PISanofi Innovation Awards ProgramSanofi S.A. · 2019–2020BioPharma AllianceBP 204239-01
- KPNuclear Functions of BCL10 and MALT1 and Their Potential for Therapeutic Intervention in Non-Hodgkin's Lymphoma (DoD Career Development Award)U.S. Department of Defense · 2015–2020W81XWH-15-1-0418
- KPDefining the role of BTG1 mutation in driving a new form of therapy-resistant DLBCLs.Leukemia & Lymphoma Society · 2018–2020LLS 3384-19
- PITRANSCRIPTIONAL REGULATION BY HEMATOPOIETIC BTB TRANSCRIPTION FACTORSChemotherapy Foundation, Inc. · 2018–2020CFI 181146-02
- KPMutations Disrupting Gene Enhancer Epigenetic Complexes as Drivers of LymphomagenesisLeukemia & Lymphoma Society · 2017–2020Career5469-18
- Co-IIntegrative Single-cell Analysis of Hematological MalignanciesDaiichi Sankyo Co., Ltd. · 2018–2020ContractDS 192276-01
- PIJanssen-Cornell Subrecipient - Subaward Agreement Amendment No. 1 (Related to WRG# 192179)Dana-Farber Cancer Institute · 2019–2020ContractSRA 192205-01
- MPILETSSGo: Lymphoma-on-Chip Engineered Technology for Single-Organoid Sequencing and GenomicsNational Cancer Institute · 2017–2020 · via Cornell University - IthacaR33CA212968-03
- MPIMOU Service agreement for personnel cost for Katerina HatziMemorial Sloan Kettering Cancer Center · 2019–2019ContractSA 200691-01
- KPElucidating the Etiologic Role of Linker Histone Mutations in Hematological MalignancyStarr Cancer Consortium · 2016–2019I9-A9-062
- Sub-PIDr. Ralph and Marian Falk Medical Research Trust Awards Programs - Catalyst AwardDr. Ralph and Marian Falk Medical Research Trust · 2018–2019 · via LLSLLS 180230-01
- KPeRNA Processing by Integrator in Lymphoma PathogenesisNational Cancer Center, Inc. · 2017–2019FellowshipNCC 17060880-01
- KPRole of histone demethylated LSD1 as an epigenetic dependency in lymphomaNational Cancer Institute · 2016–2019K99CA212276-02
- KPUse of Chromatin Accessibility Maps to Discover New Regulatory Circuits in Aggressive B Cell LymphomasNational Cancer Institute · 2017–2019FellowshipF31CA220981-02
- PITargeting EZH2 in Germinal Center Derived B-Cell LymphomaNational Cancer Institute · 2014–2019· 3 renewals
- PITranscriptional Targeting in Cancer TherapySamuel Waxman Cancer Research Foundation · 2017–2019No publications yetSWCRF 180328-07
- MPICohesin Regulatory Proteins and Chromosomal Architecture in Normal and Malignant B-CellsNational Cancer Institute · 2018–2019R01CA228528-01
- PIJanssen MALT1 Collaborative ProjectJanssen Biotech Inc. · 2018–2019ContractBP 192179-01
- KPRole of BTG1 Mutations in LymphomagenesisLymphoma Research Foundation · 2017–2019FellowshipLRF 17030307-01
- MPIECOG-ACRIN Integrated Leukemia Translational Science CenterNational Cancer Institute · 2014–2019 · via Montefiore Medical CenterU10CA180827-05
- Sub-PICore C: Consortium For The Study of Chromatin Biology And Epigenetic Training In Hematological MalignanciesLeukemia & Lymphoma Society · 2015–2018 · via University of Florida7006-13
- Sub-PIProject 6: Clinical Epigenetics in Hematological MalignanciesLeukemia & Lymphoma Society · 2015–2018 · via University of Florida7006-13
- Sub-PIMALT1 Inhibitors for the Treatment of Chemo-Resistant ABC-DLBCLNational Cancer Institute · 2013–2018 · via Dana-Farber Cancer InstituteR01CA182736-05
- KPHERO - Differential Effects on Homozygous Twin Astronauts Associated with Differences in Exposure to Spaceflight FactorsNational Aeronautics and Space Administration · 2014–2018NNX14AH50G
- KPRole of TET Proteins in Mature B Cells and LymphomagenesisLymphoma Research Foundation · 2016–2018LRF 16030472-01
- KPCohesin Complex Proteins in LymphomagenesisLymphoma Research Foundation · 2015–2018FellowshipLRF 180151-02EWOF
- MPIRole of TET 2 Mutations in the Pathogenesis and Treatment of AMLNational Cancer Institute · 2013–2018 · via Sloan-Kettering Institute for Cancer ResearchR01CA173636-05
- PITranscriptional Regulation by Hematopoietic BTB Transcription FactorsChemotherapy Foundation, Inc. · 2016–2017CFI 16040656-02
- KPEpigenetic Control of B-Cell Differentiation and Lymphomagenesis by Polycomb ComplexesAmerican Society of Hematology Inc · 2015–2017ASH 15020146-3
- KPDelineating Clinical Response with Single-Cell OmicsAbbVie Inc. · 2016–2017ContractAbbvie RAA
- KPEpigenome Interactions in Complex Neurogenetic DisordersNational Institute of Neurological Disorders and Stroke · 2011–2017R01NS076465-04
- PILincMHeM-Role of DNA Methylation in the Regulation of lincRNAs in Hematological MalignanciesUniversity of Navarra · 2013–2016UoN 14030277-01
- PITargeting the Heat Shock Response for the Therapy of DLBCLNational Cancer Institute · 2011–2016R01CA155226-05
- Sub-PIChromatin Mechanisms and Epigenetic Targeting in Hematological MalignanciesLeukemia & Lymphoma Society · 2012–2015 · via Northwestern University7006-13
- PITranscriptional Silencing by the BCL6 OncoproteinNational Cancer Institute · 2010–2015R01CA104348-10
- KPCenter on the Microenvironment and MetastasisNational Cancer Institute · 2009–2015 · via Cornell University - IthacaU54CA143876-05
- PIMolecular Targeting of Diffuse Large B-cell LymphomaNational Cancer Institute · 2010–2014R01CA143032-05
Honors & distinctions
- Ernest Beutler Lecture and Prize · American Society of Hematology · 2020
- Member · American Society for Clinical Investigation · 2009
- Member · Association of American Physicians
Clinical research
Completed & closed trials (1)
- PIRole of chromatin remodeling complex BAF in immunity and lymphomaWeill Medical College of Cornell University · CLOSED TO ACCRUAL (as of 2025)
Available technologies
News mentions
- A Unifying Mechanism for Cancer-Driving MutationsOctober 28, 2026
A family of mutations seen in about 20% of human cancers drives malignancy by changing the accessibility of genes to a particular regulatory protein, according to a study by Weill Cornell Medicine investigators.
- Anticancer Drugs Could Make Immunotherapies More EffectiveDecember 5, 2024
An emerging class of anticancer drugs called EZH2 inhibitors may greatly enhance the potency of some cancer immunotherapies, according to a preclinical study led by Weill Cornell Medicine lymphoma researchers.
- NIH Grant Will Support Lymphoma ResearchAugust 15, 2024
Weill Cornell Medicine has received a five-year, $12.4 million grant from the National Cancer Institute, part of the National Institutes of Health, for an extensive program of basic and translational research on the biology of diffuse large B-cell lymphoma (DLBCL), the most common form of lymphoma.
- Commercial Astronauts Shed Light on Flights’ Health Impacts and Create Spaceflight AtlasJune 11, 2024
Molecular and physiological changes in space travelers reveal new targets for aerospace medicine and can guide new missions, according to the results of a massive international research endeavor by investigators at Weill Cornell Medicine, SpaceX, and other organizations.
Show 17 more mentions
- Faculty Members Honored with Distinguished AwardsMay 16, 2024
Weill Cornell Medicine faculty members and alumni were honored with awards for their exemplary achievements in research, education and patient care during the institution’s commencement activities on May 15 and 16.
- Discovery Suggests New Strategy Against Follicular LymphomaMarch 28, 2024
A team led by researchers at Weill Cornell Medicine has identified important drivers of the transformation of a type of blood cancer called follicular lymphoma from a slow-growing form to the aggressive form it takes in some patients.
- Adding Epigenetic Drug to Standard Chemotherapy Was Effective in Pilot Study for T-cell LymphomaMay 4, 2023
Nearly 90 percent of patients with an aggressive subtype of non-Hodgkin lymphoma had their cancer go into remission in a small phase 2 clinical trial testing a treatment aimed at making chemotherapy more effective, according to Weill Cornell Medicine and NewYork-Presbyterian investigators.
- Weill Cornell Medicine Receives Grants to Advance Lymphoma ResearchFebruary 9, 2023
Two new grants from The Leukemia & Lymphoma Society (LLS) will support Weill Cornell Medicine’s pathbreaking research on the origins of lymphomas and on treatments that exploit these cancers’ biological vulnerabilities.
- Lymphoma Mutation Yields Super-Competitive Immune CellsJanuary 20, 2023
The key to understanding how the most aggressive lymphomas arise and resist current therapies may lie in mutations that disrupt a critical natural selection process among antibody-producing B cells.
- Study Reveals Cause, Potential Precision Therapies for Aggressive Type of LymphomaMay 25, 2022
DNA mutations are essential to the rapid development of an array of antibody-producing immune cells called B cells that collectively can recognize a vast number of specific targets. But this process can go awry in people with a mutation in a gene called SETD2, leading to a type of aggressive blood cancer.
- Lymphoma Cell Metabolism May Provide New Cancer TargetJanuary 3, 2022
Aggressive and relatively common lymphomas called diffuse large B cell lymphomas (DLBCLs) have a critical metabolic vulnerability that can be exploited to trick these cancers into starving themselves, according to a study from researchers at Weill Cornell Medicine and Cornell’s Ithaca campus.
- Antibody-Producing B Cells May be "Predestined" for their FatesSeptember 23, 2021
The master regulator behind the development of antibody-producing cells has been identified in a study by investigators at Weill Cornell Medicine. The findings provide new insight into the inner workings of the immune system and may help understand how tissues develop and how certain cancers arise.
- Scientists Discover a Key Genetic Driver of LymphomasDecember 9, 2020
Mutations in proteins called histone H1, which help package DNA in chromosomes, are a frequent cause of lymphomas, according to a study led by researchers at Weill Cornell Medicine, NewYork-Presbyterian and The Rockefeller University. The findings could lead to new approaches to treating these cancers.
- Studies Reveal Clues about Preventing Spaceflight-Related RisksNovember 25, 2020
Space travel, illnesses like COVID-19, and climbing Mount Everest can trigger the body’s stress response systems in similar ways, according to new studies by Weill Cornell Medicine, space agencies and many other investigators.
- American Society of Hematology Recognizes Weill Cornell Physician-Scientist for Advancing Treatment of Blood Cancers with Epigenetic ResearchSeptember 2, 2020
Dr. Ari Melnick, the Gebroe Family Professor of Hematology/Oncology at Weill Cornell Medicine, has been awarded the American Society of Hematology's (ASH) 2020 Ernest Beutler Lecture and Prize for advancing treatment of acute myeloid leukemia through epigenetic research.
- Scientists Build the First Global Database and Roadmap for CAR Therapy Clinical TrialsJanuary 6, 2020
Weill Cornell Medicine scientists have built the first global database of clinical trials testing a rapidly expanding approach to cancer treatment that involves genetically modifying immune cells to recognize specific targets on a patient’s cancer cells and attack them.
- Scientists Find Core Vulnerability In Aggressive LymphomasSeptember 4, 2019
The most common type of non-Hodgkin lymphoma depends for its aggressive growth and survival on an enzyme that can be therapeutically targeted with a novel compound developed at Cornell University, scientists at Weill Cornell Medicine and Cornell’s Ithaca campus have discovered.
- A One-Two Epigenetic Punch Against Aggressive Acute Myeloid LeukemiaAugust 28, 2019
Scientists at Weill Cornell Medicine have developed a system that uses cancer patients’ own cells to evaluate the efficacy of treatments. The scientists used their new testbed to show that a two-drug combination potentially would benefit many patients with acute myeloid leukemia (AML).
- Blocking Ancient Stress Gene May Aid Cancer TreatmentMay 9, 2019
A gene that originally evolved to help vertebrates’ early ancestors respond to stress is co-opted by cancers to help them resist treatment, according to a study by Weill Cornell Medicine investigators.
- Astronaut Twins Study Yields New Insights, Algorithms and Portable DNA Sequencing ToolsApril 11, 2019
Long-term spaceflight causes more changes to gene expression than shorter trips, especially to the immune system and DNA repair systems, according to research by Weill Cornell Medicine and NASA investigators as part of NASA’s Twins Study, which followed the only set of identical twin astronauts for more than two years.
- Two Advances in Understanding Lymphomas May Lead to New TherapiesJanuary 23, 2019
New studies from Weill Cornell Medicine researchers have revealed the importance of two gene-regulation proteins in the development of common immune cell cancers called lymphomas.
Mentoring
- LVLeandro VenturuttiPostdoc mentee · 2021–2021
- RGRebecca GoldsteinPharmacology (PhD) · Class of 2015
- NTNisha Tharu FernandoPharmacology (PhD) · Class of 2015
External relationships
Advisory/Scientific Board Member
Janssen Global Services, LLC
Other Interest
Treeline Biosciences INC
Other
AstraZeneca Pharmaceuticals LP · Casma Therapeutics, Inc. · Daiichi Sankyo, Inc. · Exscientia PLC · Ipsen Bioscience · Treeline Biosciences INC